HUTCHMED (China) (HMDCF) Dividends payables (2018 - 2019)
HUTCHMED (China)'s (HMDCF) quarterly Dividends payables came in at -$14.6 million in Q4 2019, down 1240.02% year-over-year from $1.3 million in Q4 2018, and down 1240.02% quarter-over-quarter from $1.3 million in Q4 2018.
Powered by 
Analysis
HUTCHMED (China) (HMDCF) Dividends payables (2018 - 2019) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Dividends payables for 2 consecutive years, with -$14.6 million the latest figure, recorded in Q4 2019.
- On a quarterly basis, Dividends payables fell 1240.02% year-over-year to -$14.6 million in Q4 2019; TTM through Dec 2019 was -$14.6 million, a 1240.02% decrease from a year earlier, with the FY2019 full-year figure at -$14.6 million, down 1240.02% from the prior year.
- Dividends payables was -$14.6 million for Q4 2019 at HUTCHMED (China), down from $1.3 million in the prior quarter.
- Over five years, Dividends payables peaked at $1.3 million in Q4 2018 and troughed at -$14.6 million in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dividends payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.51 Bn | 197.52 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.48 Bn | 178.30 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.45 Bn | 124.60 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.72 Bn | 49.59 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.31 Bn | 30.31 Bn | 1.16 Mn | - |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | - |